Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glechoma longituba total flavonoids capsule is a botanical drug candidate developed by the Institute of Radiation and Radiation Medicine, Academy of Military Medical Sciences, for the treatment of urinary tract stones. It is derived from *Glechoma longituba* (Lian Qian Cao), a plant used in Traditional Chinese Medicine (TCM) for its litholytic and diuretic properties. The capsule contains the total flavonoid fraction, which is believed to promote the passage of ureteral and renal pelvic stones, particularly in patients presenting with damp-heat syndrome. It has been evaluated in Phase III clinical trials in China for urolithiasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glechoma longituba total flavonoids capsule.